Dry 22 percent: how to match potency to the patient and why titration is necessary

• How much evidence. 4 works from 2021 to 2025, all listed in the table below along with the model.
• What has not been shown. It has not been shown that a higher declared percentage on the label means stronger or better therapeutic effects. The evidence material regarding the potency of the raw material concerns almost exclusively adverse effects and non-medical use, not effectiveness.
• What you won’t find here. Dosage recommendations or strain indications. The selection is determined by the attending physician, and cannabis flower is a raw material dispensed only by prescription.
• How to read this. The result of a study on rodents or in cell culture does not directly transfer to a patient taking the flower, and the column with the model indicates what the work was actually about.

What does the number 22 percent on the flower label describe?

The number describes the raw material, not the patient’s dose. The manufacturer declares how much tetrahydrocannabinol is contained in one hundred grams of flower after heating, and presents it as a single nominal value with an allowable deviation. Nothing in this number indicates how much substance will enter the bloodstream or how a specific person will react to it.

In the dried flower, the compound mainly exists in its acidic form, which does not act like the form that occurs after heating. Only heating cleaves the carboxyl group and converts it into the active form, so the manufacturer’s declaration refers to the content after this transformation, not to what is visible in the cold raw material. The difference between the declaration and the laboratory measurement is further developed in a separate page about twenty percent flower.

The declaration of 22 percent is not a measurement of a specific batch. With an allowable deviation, the THC content in such an item falls within the range of 19.8-24.2%, meaning the round number in the name is the midpoint of the range, not a laboratory reading.

This page does not list any items from the offer. The composition of the register changes from month to month, as permits expire and deliveries may be suspended, so the current list of strains available in pharmacies is maintained by the strain cluster hub.

How is the potency of the flower matched to a specific patient?

This is determined by the attending physician, not the number on the package. The selection involves titration: the patient starts with a small dose, observes the body’s response, and the physician adjusts the exposure only after this observation. The declared percentage is one of the input data in this process, not its goal or result.

Titration is a slow process of reaching the smallest exposure that provides the expected relief. Between successive steps, enough time is left for the previous step to show its full effect, as an assessment made too early describes only the beginning of the response. The size of the step matters less than whether the patient can notice that the previous one was sufficient.

The reason this cannot be skipped lies with the patient, not the raw material. Absorption, the rate of liver metabolism, the density of cannabinoid receptors, and concurrently taken medications differ among individuals enough that the same dose of the same flower results in different concentrations in the blood and different sensations. None of these factors are visible on the label.

The declared percentage indicates how much active substance is contained in a unit mass of raw material, not how much will reach the bloodstream. The route of administration, inhalation technique, and losses on the device shift this value downward in a way that no one measures with the patient. Thus, two people using the same package encounter different exposures, and titration leads them to different places.

Why does treatment start with a small dose?

Because before the first attempt, no one knows how this patient will react. A too large initial exposure causes symptoms that would not occur with a smaller one, and removes the possibility of checking whether a smaller exposure was already sufficient. The order is irreversible: it is easier to add more the next day than to reverse an unpleasant episode.

The asymmetry of costs is clear. A dose that is too small costs a day or two of delay, as the next step will happen anyway. A dose that is too large costs an unpleasant episode, sometimes one that leads the patient to stop treatment altogether. Adverse effects occur at exposures lower than those at which relief stops increasing, so starting from the bottom leads to encountering them earlier and more gently.

The second reason is a reserve for the future. The body’s response weakens with repeated exposure, so a patient who starts high reaches the limit sooner, above which there is no further to go. The smallest sufficient exposure is not a saving, but a way to ensure that treatment has a reserve for the coming months.

The pace of assessment is determined by the route of administration, not the percentage on the label. After vaporization, the response picture is complete even in the same session, while after ingestion, it takes hours, and this difference determines how closely one can take the next steps.

What is tolerance and why does it change the meaning of the same number?

Tolerance is the weakening of the response to repeated exposure of the same magnitude. It is not a property of the flower, but of the organism, so the number on the label remains constant, while what the patient feels after the same dose changes over the course of treatment. Thus, the same number means something different at the beginning and after a year.

The mechanism is described on the receptor side. Regular exposure decreases the density and sensitivity of type one cannabinoid receptors, so the same amount of substance encounters fewer sites where it can act, and the response is weaker. After a break in administration, the receptors return, which is why tolerance is reversible, although the rate of return can vary among individuals.

The effect concerns exactly this number. For a person who is just starting, flower with a content of 22 percent may be the upper limit of what they can tolerate without adverse effects. For a patient who has been treated for a year, the same item may be a normal working level from which the conversation about change begins. The label does not carry this information and cannot carry it, as it describes the raw material, not the treatment history.

The word tolerance appears in this context in two meanings and it is better to separate them. Manufacturer tolerance is the allowable deviation of the declaration, which is a matter of measuring the raw material. Organism tolerance is the weakening response, which is a matter of the patient’s physiology. The overlap of the declaration ranges is addressed in a separate page about eighteen percent flower.

Does the declared percentage change the onset and duration of action?

No. The declared percentage changes how much substance is contained in a dose of a given mass, not when the action begins and how long it lasts. The course is determined by the route of administration, the same for weaker and stronger raw materials, so changing to a stronger item does not shift the clock.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode lasts six, sometimes eight hours. This leads to the most common mistake with oral administration: anyone who thinks after thirty minutes that nothing is happening and adjusts the dose will receive both doses at once. The above ranges describe the route of administration, not this strain; pharmacokinetic studies for a single cultivar have not been published.

For titration, this results in a practical limit. The step must be assessed within the appropriate window for the chosen route, otherwise the assessment concerns something different than what it was meant to measure. With oral administration, a premature conclusion about a lack of effect can lead to unpleasant episodes in the first days of treatment, and it is this, not the potency of the raw material, that requires correction.

What is known and what is not known about the relationship between raw material potency and effect?

What is mainly known is what potency does in an unfavorable direction. The evidence material collected for higher concentrations mainly concerns psychosis, addiction, and non-medical use, while works on therapeutic applications are few and contradictory. The certainty of these findings is often assessed by the authors themselves as very low.

The discrepancies between these works are information, not a flaw. A review published in 2025 in the Annals of Internal Medicine (PMID:40854216) found that among studies on therapeutic use, nearly half indicated benefits for anxiety and depression, but some of the same works simultaneously described unfavorable associations, and over 95 percent of the included material had moderate or high risk of systematic error.

None of these works, however, tells the physician which potency to choose for which patient. All compare groups of people using weaker and stronger products, not two pharmacy items differing solely in declaration. Hence the role of titration: in the absence of decisive data on potency selection, the only available method remains careful observation of the individual patient.

The very division of potency into categories used in the literature is discussed in a page about twenty-five percent flower, and the increase in concentrations in successive years is addressed in a page about thirty percent flower.

What adverse effects are associated with higher potency raw material?

For a specific percentage threshold, such data is not available. Reports are collected for products with a batch number, not for potency ranges, and available reviews compare groups of users, not pharmacy items. However, it is known that it is the adverse effects that practically define the limit of the next step.

Reports of adverse effects are collected for medicinal products with a batch number, not for strain names, so the following concerns cannabis flower as a group of raw materials. The most commonly reported effects include dry mouth, red eyes, and increased heart rate. Less frequently described are dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory, as well as anxiety that increases with dosage. A separate issue is concurrently taken medications, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide numerical frequencies for these symptoms, as public compilations for cannabis flower in Poland do not separate them by individual products.

In titration, these symptoms serve as feedback signals. Their appearance after increasing the dose means that the step was too large for this patient at this moment in treatment, not that the flower is defective. The decision to reverse the step, take a break, or change the item belongs to the attending physician. The relationship between potency and the frequency of these symptoms is further developed in a separate page about twenty-seven percent flower.

Who decides on the selection of potency in a specific treatment?

The attending physician. Cannabis flower is a pharmaceutical raw material dispensed by prescription in the Rpw category, so whether a 22 percent potency item will appear in a given treatment is determined by the prescription written after examination, not by the patient’s choice or the description on the website.

This page explains the mechanism and that is where it ends. It will not provide the number of grams, number of inhalations, or daily breakdown, as such a determination requires knowledge of the diagnosis, accompanying diseases, and other medications being taken, which no informational text knows. Changing to a stronger item independently bypasses exactly this knowledge.

It is also worth distinguishing between two shelves with similar names. Prescription cannabis flower is different from cannabis flower available without a prescription, in which the tetrahydrocannabinol content does not exceed the statutory threshold and which is collected in a separate category of flower in the store. The number from this page concerns only the former shelf.

The selection of potency does not end with a single choice. During treatment, both the patient and the therapy goal change, so an item selected six months earlier may be reassessed, again in conversation with the physician, not by comparing numbers from two labels.

Frequently asked questions

Does a higher declared percentage mean stronger therapeutic action?

It has not been shown that a higher declared percentage on the label means stronger or better therapeutic effects. The evidence material regarding the potency of the raw material concerns almost exclusively adverse effects and non-medical use, not effectiveness, and works on therapeutic applications are few and yield mixed results. The authors of both the latest reviews assessed the certainty of the evidence as very low. There is also no study that compared two pharmacy flowers differing solely in declared content.

What does titration involve with prescription flower?

It involves a slow process of reaching the smallest exposure that provides the expected relief. The patient starts with a small dose and increases it only when the previous step has shown its full effect. The pace and size of the steps are determined by the attending physician, as they depend on the diagnosis and other medications being taken.

Why does the same number mean something different for a person treated for a year?

Because the body’s response to repeated exposure weakens. Regular intake decreases the density and sensitivity of cannabinoid receptors, so the same dose produces a weaker effect than at the beginning of treatment. The label describes the raw material and does not change with the patient’s history.

Are manufacturer tolerance and organism tolerance the same?

No. Manufacturer tolerance is the allowable deviation from the declared value, which is a matter of measuring the raw material. Organism tolerance is the weakening response to repeated exposure, which is a matter of the patient’s physiology. Both meanings can be confused, although they concern completely different things.

Can a patient change to a stronger flower on their own?

No, not on their own. Cannabis flower is dispensed by prescription, so switching to another declaration requires a prescription and a conversation with the attending physician. A change made independently bypasses the assessment of accompanying diseases and other medications being taken.

Where can I check which items of this potency are currently available?

In the strain cluster hub, which collects the current list of raw material available in Polish pharmacies. The composition of the register changes over time, as permits expire and deliveries may be suspended, so the list included in this article would become outdated faster than it could be corrected.

Cannabis flower is a pharmaceutical raw material dispensed by prescription in the Rpw category. The material is informational and does not replace medical advice or recommendations from the attending physician. The editorial text was prepared by the editorial team of ubucha.pl.